Allarity Therapeutics (ALLR) said Thursday it reached a final settlement with the US Securities and Exchange Commission regarding the investigation into its past disclosures about interactions with the US Food and Drug Administration concerning its 2021 application for Dovitinib.
Under the settlement, which follows a preliminary agreement in January, Allarity said it agreed to an administrative cease-and-desist order without admitting or denying any wrongdoing.
The company said previously that it agreed to pay a one-time civil penalty of $2.5 million to resolve the investigation. The amount does not affect its outlook, Allarity said, adding that it continues to expect its cash position to support operations into 2026.
Shares of Allarity were up about 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.